Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

perone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 2011 Today, the Access Group--a leading health care ... of 2 business entities, Promidian and Strategic Selling Solutions ... leaders. The Access Group was formed ... life sciences industries to provide full-service strategy and communications ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s ... test has been approved by New York State,s Department ... state. It is believed to be the first molecular ... to be approved by the state.   ...
... March 17, 2011 Delta Point, Inc., a consulting ... business relationships, has named Ed Weimer as Executive Account ... for his ability to highly motivate, develop and inspire ... strategic vision to contribute to the organization,s goals. ...
Cached Biology Technology:Introducing the Access Group and Its New Business Entities 2Introducing the Access Group and Its New Business Entities 3Introducing the Access Group and Its New Business Entities 4Introducing the Access Group and Its New Business Entities 5Introducing the Access Group and Its New Business Entities 6New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 2New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 3Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... that animals living at high latitudes grow better than ... is more nutritious. The study, published in the February ... novel explanation for Bergmann,s Rule, the observation that animals ... Ever since Christian Bergmann made his observation about latitude ...
... available in Spanish . , Pistachios, almonds and ... a yeast called Pichia anomala . Laboratory and ... (Sylvia) Hua have shown that the yeast competes successfully for ... unwanted mold, Aspergillus flavus . A. ...
... Figs and fig wasps have evolved to help each other ... wasp larvae can safely develop, and in return, the wasps pollinate ... eggs but fails to pollinate the fig? The trees get ... wasps inside, reports a Cornell University and Smithsonian Tropical Research Institute ...
Cached Biology News:Better food makes high-latitude animals bigger 2Trees retaliate when their fig wasps don't service them 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: